Clinical trials: Interstitial Lung Fibrosis
Idiopathic Pulmonary Fibrosis
Beneficial Effects of Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a devastating disease marked by progressive lung scarring leading to multiple life-altering sequelae.
- Trial name
- NCT01107028
- Testing
- Standard pulmonary rehabilitation program
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Jewish Health
Fibrosis Lung
Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrotic lung tissue and how this information can be used to better diagnose…
- Trial name
- NCT06940427
- Testing
- FAPI tracer, PET/MRI
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Wisconsin, Madison
Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis Cohort of TCM
This study, based on past registration records, evaluates the clinical efficacy of traditional Chinese medicine in treating IPF in the real world, identifies advantageous populations and clinical targets, and provides references…
- Trial name
- NCT07162870
- Testing
- Traditional Chinese medicine (TCM), Non-traditional Chinese medicine (non-TCM)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Idiopathic Pulmonary Fibrosis
To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers
An open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between DWN12088 and Pirfenidone or Nintedanib in healthy volunteers
- Trial name
- NCT04888715
- Testing
- DWN12088, Pirfenidone, Nintedanib
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Interstitial Lung Disease
Pulmonary Rehabilitation in Interstitial Lung Disease
Interstitial lung disease (ILD) is a highly disabling group of conditions including idiopathic pulmonary fibrosis (IPF), acute and chronic interstitial pneumonias, connective tissue diseases and sarcoidosis.
- Trial name
- NCT00168285
- Testing
- Pulmonary Rehabilitation
- Where
- 2 sites in Australia
- Volunteers
- 56 people
- Sponsor
- The Alfred